McKesson Corporation

According to J.P. Morgan, McKesson (NYSE: MCK) is rated Overweight. J.P. Morgan said that as part of McKesson Week it hosted a conference call with CEO John Hammergren today. “Our rating on McKesson is Overweight. We continue to point to the positive fundamental outlook for the drug distribution...

According to a recent report by J.P. Morgan, during a McKesson conference call (NYSE: MCK), CEO, John Hammergren reported the company has no plans to sell or spin their business and further discussed recent trends and management outlook. The conference call lead J.P. Morgan to reiterate a $84.17...

In recent reports, J.P. Morgan has increased the price target on McKesson (NYSE: MCK) from $93.00 to $100.00 and F2012 EST from $5.75 to $6.18. In the report, J.P. Morgan said, "After the close, MCK reported solid 4QF11 results and issued above-consensus initial guidance for F2012. While the...

JP Morgan has raised the price target on McKesson Corporation (NYSE: MCK) from $93 to $100 and maintains its Overweight rating.

Goldman Sachs has raised the price target on McKesson Corporation (NYSE: MCK) from $84 to $87 and maintains its Buy rating.

JP Morgan has raised the price target on McKesson Corporation (NYSE: MCK) from $87 to $93 and maintains its Overweight rating.

Among the distributors, J.P. Morgan said that it favors McKesson Corporation (NYSE: MCK) and Cardinal Health, Inc. (NYSE: CAH). “We continue to believe that MCK is underappreciated, as the distribution business continues to successfully expand generic penetration and EBIT growth continues to be the...

Following the regional HIMSS event, Jefferies & Company is recommending Allscripts Healthcare Solutions (NASDAQ: MDRX) and McKesson Corporation (NYSE: MCK). “On the physician side Allscripts (Buy) appeared to be the primary vendor used by attendees,” Jefferies & Company writes. “We...